Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr11.05 SEK
Change Today 0.00 / 0.00%
Volume 92.2K
As of 11:29 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

active biotech ab (ACTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/23/14 - kr35.68
52 Week Low
04/16/15 - kr8.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTIVE BIOTECH AB (ACTI)

Related News

No related news articles were found.

active biotech ab (ACTI) Related Businessweek News

No Related Businessweek News Found

active biotech ab (ACTI) Details

Active Biotech AB (publ) develops drugs for the treatment of neurodegenerative diseases and cancer. The company has two projects in clinical development, such as laquinimod and tasquinimod. The Laquinimod project is a novel immunomodulatory compound for the treatment of neurodegenerative diseases; and the Tasquinimod project is an immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The company is also developing Paquinimod, an oral immunomodulatory compound for the treatment of systemic sclerosis; and RhuDex, an orally active compound for the treatment of autoimmune diseases. Its preclinical project product is ISI–Inhibition of S100 Interactions for producing patentable chemical compounds that interact with one of the quinoline compounds’ target molecules. Active Biotech AB (publ) is headquartered in Lund, Sweden.

56 Employees
Last Reported Date: 04/23/15

active biotech ab (ACTI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.0M
Compensation as of Fiscal Year 2013.

active biotech ab (ACTI) Key Developments

Teva Pharmaceutical Industries Ltd. and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS

Teva Pharmaceutical Industries Ltd. and Active Biotech announced the first patient has been enrolled in the study ARandomized Placebo-controlled Trial Evaluating Laquinimod in PPMS, Gauging Gradations In MRI and Clinical Outcomes, a Phase II study to evaluate laquinimod, an investigational, oral, immune modulator, for the treatment of primary progressive multiple sclerosis. Currently there are no approved treatments for PPMS, representing a condition with a high unmet need. PPMS affects approximately 15% of all MS patients and is characterized by the worsening of neurologic function without distinct relapses. Unlike patients with relapsing-remitting MS, those with PPMS tend to have more lesions in the spinal cord than in the brain and these brain lesions usually contain fewer inflammatory cells. In addition, all studies evaluating RRMS treatments in patients with PPMS have failed to prove effective for this condition. ARPEGGIO is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of once-daily, oral laquinimod in patients with PPMS. The study’s primary endpoint is percent brain volume change through MRI analysis. The trial will enroll approximately 375 patients in the U.S., Canada, and Europe. Additional details on the study design will be presented at the AAN Annual Meeting in Washington, D.C. on April 23, 2015 during Poster Session 7.

Active Biotech AB Reports Earnings Results for the First Quarter of 2015

Active Biotech AB reported earnings results for the first quarter of 2015. For the quarter, the company reported net sales of SEK 2.9 million against SEK 2.1 million a year ago. Operating loss was SEK 57.4 million against SEK 29.2 million a year ago. Loss for the period was SEK 58.0 million or SEK 0.64 per share against SEK 60.2 million or SEK 0.80 per share a year ago.

Active Biotech and Ipsen Announce Top Line Results of the 10TASQ10 Study

Active Biotech and Ipsen announced top line results of the 10TASQ10 study. While the study showed that tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 0.80) in patients with metastatic castration resistant prostate cancer (mCRPC) who have not received chemotherapy, tasquinimod did not extend overall survival. Efficacy results together with preliminary safety data do not support positive benefit risk balance in this population. Therefore the companies have decided to discontinue all studies in prostate cancer. Full results will be presented at an upcoming scientific conference. The outcome of the 10TASQ10 study is a major disappointment based on the promising phase II results. However, the data at hand is unambiguous and cannot motivate further development of tasquinimod in this patient population.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACTI:SS kr11.05 SEK 0.00

ACTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACTI.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 91.2x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTIVE BIOTECH AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at